148 related articles for article (PubMed ID: 35954351)
1. Clinical Impact of Dual Time Point
Einama T; Yamagishi Y; Takihata Y; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Kouzu K; Nakazawa A; Iwasaki T; Shinto E; Ishida J; Ueno H; Kishi Y
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954351
[TBL] [Abstract][Full Text] [Related]
2. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
4. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
5. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.
Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H
Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.
Jin F; Zhu H; Fu Z; Kong L; Yu J
Onco Targets Ther; 2016; 9():2993-9. PubMed ID: 27284249
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
[TBL] [Abstract][Full Text] [Related]
9. Utility of
Yamagishi Y; Yamasaki T; Ishida J; Moriya T; Einama T; Koiwai T; Fukumura-Koga M; Kono T; Hayashi K; Ueno H; Yamamoto J; Tsuda H
Ann Surg Oncol; 2020 Aug; 27(8):2698-2710. PubMed ID: 32124121
[TBL] [Abstract][Full Text] [Related]
10. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
11. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
[No Abstract] [Full Text] [Related]
12. The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.
Lee JK; Min KJ; So KA; Kim S; Hong JH
J Ovarian Res; 2014 Feb; 7():15. PubMed ID: 24499648
[TBL] [Abstract][Full Text] [Related]
13. Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective study.
Kobayashi K; Einama T; Tsunenari T; Yonamine N; Takao M; Takihata Y; Tsujimoto H; Ueno H; Tamura K; Ishida J; Kishi Y
Oncol Lett; 2024 Jun; 27(6):279. PubMed ID: 38699663
[TBL] [Abstract][Full Text] [Related]
14. The maximum standardized uptake value increment calculated by dual-time-point
Yonezawa N; Minamikawa T; Kitajima K; Takahashi Y; Sasaki R; Nibu KI; Komori T
Nagoya J Med Sci; 2017 Feb; 79(2):189-198. PubMed ID: 28626254
[TBL] [Abstract][Full Text] [Related]
15. Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer.
Ikejiri H; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Breast; 2022 Oct; 65():98-103. PubMed ID: 35921799
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
20. Predictive Ability of
Kiyoto S; Sugawara Y; Hosokawa K; Nishimura R; Yamashita N; Ohsumi S; Mochizuki T
Asia Ocean J Nucl Med Biol; 2016; 4(1):3-11. PubMed ID: 27904868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]